Actively Recruiting
Non-Myeloablative Stem Cell Transplant Using Alemtuzumab, 400 cGy Total Body Irradiation, and Abatacept for Severe Sickle Cell Disease and Beta-Thalassemia with Matched Donors
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2026-10-13
90
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a non-myeloablative stem cell transplant approach for patients with severe sickle cell disease or beta-thalassemia who require red cell transfusions. This study aims to increase the intensity of the transplant slightly to achieve a higher proportion of donor cells remaining long-term in recipients. The trial compares this regimen with previous transplant protocols to improve outcomes such as graft stability and reduce graft failure. The treatment includes total body irradiation at 400 cGy to better deplete the patients immune cells, combined with 1 mgkg alemtuzumab and 10 mgkg abatacept given six times to help prevent graft-versus-host disease. Donor hematopoietic cells are collected after mobilization with filgrastim. The study involves matched related donors and transplant recipients, with the goal of improving donor cell engraftment and reducing complications. Participants will undergo various assessments including blood tests to measure donor cell chimerism at multiple timepoints up to three years post-transplant. Other evaluations include monitoring blood counts, infections, graft-versus-host disease, organ function, neuropsychological well-being, pain, and reproductive health. The study will track survival and complications for up to three years, with a total study duration extending to 2035.
CONDITIONS
Brief Title
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Research Team
K
Kelly S Norris, R.N.
J
John F Tisdale, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here